Innovative intradermal injection device for lymphoscintigraphy and sentinel lymph node mapping
Breast cancer is the most diagnosed cancer in women, with over 2.3 million cases annually and significant global mortality. Accurate staging, including lymph node involvement, is critical for treatment decisions. Sentinel lymph node (SLN) mapping is the standard for assessing nodal metastasis and involves radioisotopes or fluorescent dyes.
This white paper outlines advancements in mapping and imaging for breast cancer, emphasizing the role of lymphoscintigraphy and an innovative intradermal (ID) injection device, VAX-ID®.
Some of the topics discussed in this white paper include:
Lymphoscintigraphy Techniques
Lymphoscintigraphy is a widely used imaging method for identifying SLNs, with nearly 100% success rates. Methods for administering mapping agents, radioisotopes or fluorescent dyes, include ID, intraparenchymal, and subdermal injections, each with specific characteristics.
ID injection has shown significantly higher frequency of successful localization, reduced time to initial localization through preoperative lymphoscintigraphy, and decreased time for harvesting the first SLN.
Challenges with ID Injections
ID injection, often performed using the Mantoux technique, requires expertise, standardization, and precision. therefore, the technique makes errors in depth or angle to reduce efficacy.
VAX-ID® Device
The VAX-ID® is a novel intradermal injection device designed for consistent, precise, and reliable injections. It simplifies ID injections by controlling needle depth, ensuring accurate delivery, reducing user error, and increasing the efficacy of SLN mapping. This device is proposed to standardize and improve the reliability of SLN procedures, making them safer and more accessible.